Inter Pharma (SET:IP) - Hisse Senedi Fiyatı, Haberler ve Analizler

IP Stoklara Genel Bakış

Inter Pharma Public Company Limited, Tayland'da insanlar ve hayvanlar için besin takviyesi ürünleri üretmekte, ithal etmekte ve dağıtmaktadır.

Şirket hakkında

IP temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	2/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Risk Analizi

Profit margins (1.1%) are lower than last year (6.1%)

Does not have a meaningful market cap (THB2B)

Inter Pharma Public Company Limited Rakipler

Rojukiss International

SET:KISS

฿2.7b

Thai Nippon Rubber Industry Public

SET:TNR

฿2.8b

Asian Phytoceuticals

SET:APCO

฿3.2b

S & J International Enterprises

SET:S&J

฿6.0b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Inter Pharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	฿3.70
52 Haftanın En Yüksek Seviyesi	฿7.30
52 Haftanın En Düşük Seviyesi	฿3.30
Beta	0.57
11 Aylık Değişim	-17.41%
3 Aylık Değişim	10.12%
1 Yıllık Değişim	-36.38%
33 Yıllık Değişim	-72.03%
5 Yıllık Değişim	-11.86%
Halka arzdan bu yana değişim	-6.47%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	IP	TH Personal Products	TH Pazar
7D	-7.5%	-1.7%	0.04%
1Y	-36.4%	-4.3%	2.8%

Getiri vs. Endüstri: IP underperformed the TH Personal Products industry which returned -4.3% over the past year.

Getiri vs Piyasa: IP underperformed the TH Market which returned 2.8% over the past year.

Fiyat Oynaklığı

Is IP's price volatile compared to industry and market?
IP volatility
IP Average Weekly Movement	6.3%
Personal Products Industry Average Movement	6.2%
Market Average Movement	5.0%
10% most volatile stocks in TH Market	10.9%
10% least volatile stocks in TH Market	2.5%

İstikrarlı Hisse Senedi Fiyatı: IP has not had significant price volatility in the past 3 months compared to the TH market.

Zaman İçindeki Volatilite: IP's weekly volatility (6%) has been stable over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2006	n/a	Trinnawat Thanitnithiphan	www.interpharma.co.th

Inter Pharma Public Company Limited, Tayland'da insanlar ve hayvanlar için besin takviyesi ürünleri üretmekte, ithal etmekte ve dağıtmaktadır. İnsan Sağlığı, Hayvan Sağlığı ve Hastane olmak üzere üç segmentte faaliyet göstermektedir. Şirket, tıbbi malzemeler, beslenme tedavisi, kozmetikler, ek gıdalar, probiyotik ve prebiyotik ürünler, sağlıklı gıda ürünleri, genel gıda ürünleri, tıbbi ekipman ve ilaçlar vb.

Inter Pharma Public Company Limited Temel Bilgiler Özeti

Inter Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IP temel i̇stati̇sti̇kler
Piyasa değeri	฿2.24b
Kazançlar(TTM)	฿20.39m
Gelir(TTM)	฿1.81b

109.8x

F/K Oranı

1.2x

P/S Oranı

IP aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IP gelir tablosu (TTM)
Gelir	฿1.81b
Gelir Maliyeti	฿1.14b
Brüt Kâr	฿665.39m
Diğer Giderler	฿645.00m
Kazançlar	฿20.39m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.034
Brüt Marj	36.78%
Net Kâr Marjı	1.13%
Borç/Özkaynak Oranı	11.7%

IP uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

0.6%

Mevcut Temettü Verimi

64%

Ödeme Oranı

IP Stoklara Genel Bakış

Ödüller

Risk Analizi

Inter Pharma Public Company Limited Rakipler

SET:KISS

฿2.7b

SET:TNR

฿2.8b

SET:APCO

฿3.2b

SET:S&J

฿6.0b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: ฿0.006 (vs ฿0.019 in 2Q 2023)

Investor sentiment deteriorates as stock falls 26%

New minor risk - Share price stability

First quarter 2024 earnings released: EPS: ฿0.042 (vs ฿0.066 in 1Q 2023)

Investor sentiment deteriorates as stock falls 40%

Recent updates

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: ฿0.006 (vs ฿0.019 in 2Q 2023)

Investor sentiment deteriorates as stock falls 26%

New minor risk - Share price stability

First quarter 2024 earnings released: EPS: ฿0.042 (vs ฿0.066 in 1Q 2023)

Investor sentiment deteriorates as stock falls 40%

Inter Pharma Public Company Limited Approves Dividend for the Year 2023, Payable on May 24, 2024

Now 20% overvalued

Dividend reduced to ฿0.035

Full year 2023 earnings: EPS and revenues miss analyst expectations

Inter Pharma Public Company Limited Proposes Dividend for the Year 2023, Payable on May 24, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: ฿0.037 (vs ฿0.09 in 3Q 2022)

New minor risk - Market cap size

Consensus EPS estimates fall by 32%

Second quarter 2023 earnings released: EPS: ฿0.03 (vs ฿0.10 in 2Q 2022)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 9.7% to ฿18.10

Investor sentiment deteriorates as stock falls 25%

Inter Pharma Public Company Limited Announces CFO Changes

Investor sentiment deteriorates as stock falls 22%

First quarter 2023 earnings released: EPS: ฿0.11 (vs ฿0.10 in 1Q 2022)

Upcoming dividend of ฿0.18 per share at 1.6% yield

Price target decreased by 13% to ฿18.65

Inter Pharma Public Company Limited Announces Resignation of Terdkiat Prommool as Director

Consensus forecasts updated

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: ฿0.10 (vs ฿0.086 in 2Q 2021)

Inter Pharma Public Company Limited announced that it has received THB 1.04314 billion in funding from Innobic LL Holding Company Limited

Inter Pharma Public Company Limited Approves Election of Directors

Inter Pharma Public Company Limited Announces Chief Financial Officer Changes

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to ฿26.00

High number of new and inexperienced directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Inter Pharma Public Company Limited Proposes Omission of Dividend Payment for 2021

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2021 earnings released: EPS ฿0.088 (vs ฿0.064 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ฿0.086 (vs ฿0.059 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.091 (vs ฿0.048 in 1Q 2020)

Inter Pharma Public Company Limited Approves Cash Dividends for 2020, Payable on May 18, 2020

Revenue and earnings miss expectations

Full year 2020 earnings released: EPS ฿0.26 (vs ฿0.28 in FY 2019)

Inter Pharma Public Company Limited, Annual General Meeting, Apr 26, 2021

Inter Pharma Public Company Limited (SET:IP) entered into an agreement to acquire Certain Assets of Teva Pharma (Thailand) Co., Ltd. from Teva Pharma (Thailand) Co., Ltd. for THB 160 million.

Investor sentiment improved over the past week

Inter Pharma Public Company Replaces Amornsakdi Ketcharoon with Kamtorn Sila-On as an Independent Director, Audit Committee, Chairman of the Nomination and Remuneration Committee and Corporate Governance and Sustainable Development Committee, Effective February 8, 2021

New 90-day high: ฿19.70

Independent Director has left the company

Inter Pharma Public Company Limited Notifies the Resignation of Mr. Amornsakdi Ketcharoon from Independent Director, Audit Committee, Chairman of the Nomination and Remuneration Committee and Corporate Governance and Sustainable Development Committee ,Effective from January 31, 2021

Investor sentiment improved over the past week

New 90-day high: ฿14.00

New 90-day high: ฿13.60

Third quarter 2020 earnings released: EPS ฿0.09

Interpharma Public Company Limited Announces Director Changes